Page last updated: 2024-12-08

3-hydroxylidocaine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxylidocaine: a metabolite of lidocaine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161824
CHEBI ID80567
SCHEMBL ID6243924
MeSH IDM0204219

Synonyms (15)

Synonym
acetamide, 2-(diethylamino)-n-(3-hydroxy-2,6-dimethylphenyl)-
3-hydroxylidocaine
34604-55-2
FT-0669719
2-(diethylamino)-n-(3-hydroxy-2,6-dimethylphenyl)acetamide
3-hydroxy lidocaine
CHEBI:80567
SCHEMBL6243924
DTXSID20188177
AKOS030253174
J-019676
Q26998316
3-hydroxylidocaine; lc-tdda; ce10
lidocaine-3-hydroxy 100 microg/ml in acetonitrile
PD060808

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" There were no differences in pharmacokinetic parameters for lidocaine between the UT and PB groups."( Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels.
Fujimori, M; Funae, Y; Imaoka, S; Nakamoto, T; Oda, Y, 1997
)
0.52
"Ciprofloxacin increased the mean peak concentration and area under plasma concentration-time curve of lidocaine by 12% (range [-6] to+46%; P<0."( Effect of ciprofloxin on the pharmacokinetics of intravenous lidocaine.
Ahonen, J; Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2005
)
0.33
" During the fluvoxamine phase the area under the plasma concentration-time curve (AUC) and peak concentration (Cmax) of oral lidocaine were 305% (P<0."( Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni, MH; Neuvonen, PJ; Olkkola, KT, 2006
)
0.33
" Lidocaine and metabolite concentrations were determined by liquid chromatography- mass spectrometry and pharmacokinetic (non-compartmental and compartmental) analysis was performed."( Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block.
Arthur, RM; Blea, J; Katzman, S; Knych, HK; McKemie, DS, 2023
)
0.91
"Compared to previous reports, the terminal half-life and subsequent detection time observed following administration of lidocaine in combination with epinephrine is prolonged."( Pharmacokinetics and metabolism of lidocaine HCl 2% with epinephrine in horses following a palmar digital nerve block.
Arthur, RM; Blea, J; Katzman, S; Knych, HK; McKemie, DS, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Lidocaine (Antiarrhythmic) Action Pathway4922
Lidocaine (Local Anaesthetic) Action Pathway3325
Lidocaine (Local Anaesthetic) Metabolism Pathway416
Lidocaine metabolism08

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (66.67)18.2507
2000's2 (22.22)29.6817
2010's0 (0.00)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.25 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]